Regeneron Pharmaceuticals sees major institutional investment and analyst upgrades

Regeneron Pharmaceuticals has seen significant activity from both institutional investors and market analysts. BlackRock Inc. acquired a substantial new position in the biopharmaceutical company during the second quarter, purchasing approximately 9.1 million shares valued at roughly $5.68 billion. This acquisition brings BlackRock’s ownership of the company to 8.62%.

Other institutional movements include Norges Bank establishing a position worth over $1 billion in the fourth quarter, and USA Financial Formulas acquiring a stake valued at approximately $1.13 million in the first quarter. Major firms such as Wellington Management Group LLP and Nuveen LLC also reported significant increases in their holdings.

On the analyst front, Leerink Partners raised its price target for Regeneron from $641.00 to $824.00. Other financial institutions have also adjusted their outlooks, with Cantor Fitzgerald and TD Cowen raising their price objectives, contributing to a consensus market rating of “Moderate Buy” among various research firms.